{
    "2021-12-11": [
        [
            {
                "time": "2023-10-05",
                "original_text": "Novartis Scemblix速 demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia",
                "features": {
                    "keywords": [
                        "Scemblix速",
                        "sustained response",
                        "chronic myeloid leukemia",
                        "48-week follow-up"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis Kymriah速 demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up",
                "features": {
                    "keywords": [
                        "Kymriah速",
                        "strong responses",
                        "high-risk patients",
                        "follicular lymphoma",
                        "extended study follow-up"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Novartis sees strong interest in Sandoz generics unit - Finanz und Wirtschaft",
                "features": {
                    "keywords": [
                        "Sandoz",
                        "generics unit",
                        "strong interest",
                        "Finanz und Wirtschaft"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals",
                        "investing"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}